{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:22:05Z","timestamp":1787163725951,"version":"build-2736575974"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,26]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Mucopolysaccharidosis type III, also referred to as Sanfilippo disease, is a rare hereditary lysosomal storage illness and one of the more common variants. The illness can affect all tissues and organs of the body, with the central nervous system being the most profoundly impacted. Autoimmune hemolytic anemia (AIHA) is a rare, diverse, antibody-mediated disorder characterized by the production of antibodies that target and destroy red blood cells, leading to their rapid destruction. AIHA is a prevalent and notable complication in recipients following umbilical cord blood stem cell transplantation. Immunosuppressive treatments, including intravenous immunoglobulin and rituximab, have been the primary therapeutic modalities. There is no consensus on the appropriate treatment for post-transplant severe AIHA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>This article details a 5-year-old male diagnosed with mucopolysaccharidosis type III. He developed AIHA\u2005+\u2005144 days after umbilical cord blood stem cell transplantation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Genetic testing, cranial CT, blood cell analysis, direct\/indirect antihuman globulin test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Treatment encompasses red blood cell transfusion to rectify anemia, intravenous administration of methylprednisolone, calcium gluconate, alkaline solutions, plasma exchange, rituximab, gamma globulin, and more symptomatic therapies. The symptoms of hemolysis were inadequately managed throughout the disease progression and were alleviated upon therapy with daratumumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The treatment was conducted without adverse effects, and the problem was well managed. A telephonic follow-up with the patient was conducted by our department 546 days post-discharge. The child\u2019s cognitive ability, linguistic skills, and other neurological processes remained stable without further decline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This report discusses a child with MPS III, a rare disorder characterized by complex and varied phenotypes, including distinctive facial features, short stature, cognitive regression, varying degrees of skeletal deformities, and hepatosplenomegaly. The patient has autoimmune hemolysis after umbilical cord blood transplantation. For patients who do not respond to rituximab and gamma globulin, daratumumab may be considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000044874","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T16:01:23Z","timestamp":1759248083000},"page":"e44874","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A case report on the treatment of autoimmune hemolytic anemia after CBT by daratumumab in a mucopolysaccharidosis type III patient"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3454-210X","authenticated-orcid":false,"given":"Zhuo-yang","family":"Bian","sequence":"first","affiliation":[{"name":"Graduate School, Bengbu Medical University, Bengbu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of hematology, Anhui No. 2 Provincial People\u2019s Hospital, Hefei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260602","doi-asserted-by":"crossref","first-page":"173562","DOI":"10.1016\/j.ejphar.2020.173562","article-title":"Update of treatment for mucopolysaccharidosis type III (sanfilippo syndrome).","volume":"888","author":"Kong","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"R2-20260602","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.4103\/ijo.IJO_425_22","article-title":"Mucopolysaccharidosis: a broad review.","volume":"70","author":"Nagpal","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"R3-20260602","doi-asserted-by":"crossref","first-page":"102724","DOI":"10.1016\/j.bcmd.2023.102724","article-title":"Daratumumab as a novel treatment option in refractory ITP.","volume":"99","author":"Vernava","year":"2023","journal-title":"Blood Cells Mol Dis"},{"key":"R4-20260602","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/bjh.17655","article-title":"Daratumumab in rituximab-refractory autoimmune haemolytic anaemia.","volume":"194","author":"Rieger","year":"2021","journal-title":"Br J Haematol"},{"key":"R5-20260602","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/petr.12455","article-title":"The incidence of autoimmune hemolytic anemia in pediatric hematopoietic stem cell recipients post-first and post-second hematopoietic stem cell transplant.","volume":"19","author":"Ahmed","year":"2015","journal-title":"Pediatr Transplant"},{"key":"R6-20260602","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbmt.2013.11.011","article-title":"Analysis of donor and recipient ABO incompatibility and antibody-associated complications after allogeneic stem cell transplantation with reduced-intensity conditioning.","volume":"20","author":"Watz","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"R7-20260602","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.bbmt.2013.11.014","article-title":"Autoimmune hematological diseases after allogeneic hematopoietic stem cell transplantation in children: an Italian multicenter experience.","volume":"20","author":"Faraci","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"R8-20260602","doi-asserted-by":"crossref","first-page":"e28010","DOI":"10.1002\/pbc.28010","article-title":"Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia.","volume":"67","author":"Even-Or","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"R9-20260602","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000535927","article-title":"Posttransplant autoimmune hemolytic anemia with anti-D specificity successfully treated with daratumumab: a case report.","volume":"51","author":"Frioni","year":"2024","journal-title":"Transfus Med and Hemother"},{"key":"R10-20260602","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jimd.12626","article-title":"Gene therapies for mucopolysaccharidoses.","volume":"47","author":"Rossi","year":"2024","journal-title":"J Inherit Metab Dis"},{"key":"R11-20260602","doi-asserted-by":"crossref","first-page":"100648","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting.","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"key":"R12-20260602","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2010-03-259325","article-title":"How I treat autoimmune hemolytic anemias in adults.","volume":"116","author":"Lechner","year":"2010","journal-title":"Blood"},{"key":"R13-20260602","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/rheumatology\/38.8.747","article-title":"Side-effects of long-term immunosuppression versus morbidity in autologous stem cell rescue: striking the balance.","volume":"38","author":"Niethammer","year":"1999","journal-title":"Rheumatology (Oxford)"},{"key":"R14-20260602","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3389\/fimmu.2018.00835","article-title":"Targeting B cells and plasma cells in autoimmune diseases.","volume":"9","author":"Hofmann","year":"2018","journal-title":"Front Immunol"},{"issue":"Suppl 1","key":"R15-20260602","first-page":"4936","article-title":"Anti-CD20 monoclonal antibody therapy for immune modulation across a range of autoimmune diseases.","volume":"130","author":"Macisaac","year":"2017","journal-title":"Blood"},{"key":"R16-20260602","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00277-020-04063-w","article-title":"Daratumumab for refractory warm autoimmune hemolytic anemia.","volume":"100","author":"Jain","year":"2021","journal-title":"Ann Hematol"},{"key":"R17-20260602","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clim.2016.02.009","article-title":"A role for plasma cell targeting agents in immune tolerance induction in autoimmune disease and antibody responses to therapeutic proteins.","volume":"165","author":"Rosenberg","year":"2016","journal-title":"Clin Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044874","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T18:01:27Z","timestamp":1780423287000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":17,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044874","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"2025-04-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}